The protease inhibitor darunavir prevents esophagitis and impairments in esophageal barrier function in a mouse model of GERD

Authors:

Abstract
The gastroesophageal reflux of pepsin contributes importantly to esophageal damage in patients with GERD. We have found that darunavir, a drug presently used to treat HIV, inhibits pepsin activity and, in an animal model of GERD, darunavir reduces esophageal inflammation and HIF-2α levels while preserving levels of tight junction proteins and esophageal mucosal integrity. These findings suggest that darunavir might have a role as a novel treatment for GERD.
Funding Information
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (309461/2020-0)

This publication has 39 references indexed in Scilit: